The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues, while a US biopharma group is calling for industries to boycott all non-food and medical trade with Russia.
As Russia continues its invasion of Ukraine and moves on key cities including the capital Kyiv, there are fears for the medical needs of the country’s 44 million inhabitants.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Scrip about the latest developments.
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
India and the US are the major manufacturers of finished dosages for the US market in terms of volume (China accounts for 9% of injectables), though the US relies heavily on India for solid oral dosage forms and specific generics, including lenalidomide and albuterol. Scrip talks to experts on some of the key implications of geographic concentration of production for the US market amid the specter of tariffs.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Scrip about the latest developments.
Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
